Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.575 USD | -2.46% | +1.38% | +5.97% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 101M |
---|---|---|---|---|---|
Net income 2024 * | -108M | Net income 2025 * | -134M | EV / Sales 2024 * | - |
Net cash position 2024 * | 254M | Net cash position 2025 * | 172M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.1
x | P/E ratio 2025 * |
-1.16
x | Employees | 66 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.25% |
Latest transcript on Athira Pharma, Inc.
1 day | +3.13% | ||
1 week | +4.76% | ||
Current month | +34.01% | ||
1 month | +37.50% | ||
3 months | -34.16% | ||
6 months | +72.55% | ||
Current year | +8.64% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Litton
CEO | Chief Executive Officer | 56 | 19-07-10 |
Andrew Gengos
DFI | Director of Finance/CFO | 59 | 23-05-17 |
Rachel Lenington
COO | Chief Operating Officer | 51 | 21-06-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Grant Pickering
BRD | Director/Board Member | 56 | 22-01-26 |
John Fluke
BRD | Director/Board Member | 81 | 12-12-31 |
Joseph Edelman
BRD | Director/Board Member | 67 | 20-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +10.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 2.575 | -2.46% | 343 518 |
24-05-24 | 2.64 | +3.13% | 97,741 |
24-05-23 | 2.56 | -2.29% | 108,223 |
24-05-22 | 2.62 | +3.15% | 75,479 |
24-05-21 | 2.54 | +0.79% | 55,998 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.64% | 101M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.32% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- ATHA Stock